Active substance
Glubionate
- SFDA 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| HI-CAL | 240 mg/ml | Syrup · Oral use | 1 Bottle | SAR 6.50 | NCE · Prescription | MEDICAL UNION PHARMACEUTICALS CO | Valid |
Indications — CHI Daman Drug Formulary
BREAST CANCER EARLY HORMONAL-SUPPORTIVE CARE; BREAST CANCER MET. HORMONAL-SUPPORTIVE CARE; HYPOPARATHYROIDISM; MATERNAL AND CHILD HEALTHCARE- SUPPLEMENTATION FOR MOTHER AND CHILD; MYASTHENIA GRAVIS; POMPE DISEASE (LOPD); RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS-SUPPORTIVE CARE AND ADRS MANAGEMENT
Combinations containing Glubionate
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.